The Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive Disorder

Phase 2

Recruiting

• Conditions: Depression; Treatment Resistant Depression

• Registration Number: NCT04805879
• Lead Sponsor: University of Calgary

Brief Summary

The primary goals of this proof of concept clinical trial are to determine the effectiveness, safety and tolerability of oral FMT in adults with Treatment Resistant Depression (TRD).

Detailed Description

This study is a phase 2/3, double-blinded, randomized controlled trial (RCT) in which 80 adults with TRD being treated with an approved antidepressant medication will be assigned to either FMT capsules or identically appearing placebo capsules. Participant will be followed for f for 14 weeks post FMT. This extended observation period will allow us to see, whether FMT leads to sustainable improvements in depression and changes in intestinal microbiome

Study Timeline

• Study Start: 2021-03-04
• Study First Submitted: 2021-03-11
• Study First Submitted QC: 2021-03-16
• Study First Posted: 2021-03-18
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-27
• Last Update Posted: 2023-11-28
• Primary Completion: 2024-03-04
• Study Completion: 2024-12-04

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Between 18-65 years of age:

   Participants should be at least 18 years old and not older than 65 years at the day of screening

2. Have a primary diagnosis of MDD according to the M.I.N.I. International Neuropsychiatric Interview (MINI)47

3. Medical history suggestive of Treatment Resistant Depression (TRD). (inadequate response to at least 2 approved antidepressants. at least one of which is in the current episode of depression)48

4. Have been on a current treatment with a approved antidepressant at an adequate dose for at least 8 weeks

5. A MADRS score of ≥ 19 at screening and visit 2

Additional Inclusion Criteria:

• Participants who will be included in the IBS-D cohort should have a confirmed diagnosis of IBS-D as indicated by the referring gastroenterologist.

Exclusion Criteria

• 1. Participant meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5)1 Criteria for the following conditions according to the M.I.N.I: f) Substance Use Disorder within the last 3 months. *(Criteria should include Alcohol and non-alcohol substances except Cannabis) g) Moderate or severe Substance use disorder for Cannabis use the last 3 months h) Active Anorexia Nervosa or Bulimia nervosa i) Schizophrenia or schizoaffective disorder j) Active suicidality 2. Regular intake of non-steroidal anti-inflammatory drugs, antibiotics, or iron supplements for medical purposes in the 3 months prior to study entry 3. Use of prebiotics or probiotics for medical purposes for more than 2 weeks within the last 3 months 4. Clinically diagnosed chronic gastrointestinal diseases (IBD, Crohn's disease, Ulcerative colitis, Celiac disease) 5. Conditions causing immune suppression 6. Not breastfeeding, pregnant or seeking to get pregnant during the course of this study. Be using an acceptable method of birth control (implants, injectable, combined oral contraceptives, IUDs, sexual abstinence or a vasectomized partner) 7. Reported allergy to Vancomycin or Nitazoxanide

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change in the MADRS total score	from baseline (pre-intervention) to the final visit (week 13)	To evaluate the effectiveness of adjunct oral FMT as compared to placebo with currently accepted approved therapy for depression

Secondary Outcome Measures

Name	Time	Method
GI tolerability of patients with Irritable Bowel Syndrome (IBS)	from baseline (pre-intervention) to the final visit (week 13)	GI tolerability will be assessed using the IBS Symptom Severity Scale (IBS SSS) and IBS specific Quality of Life (IBS-QoL) questionnaire
Side effects as reported on the Toronto Side Effect Scale (TSES)	from baseline (pre-intervention) to the final visit (week 13)	The tolerability of FMT will be assessed using the Toronto Side effects Scale (TSES)

Trial Locations

Locations (1)

Cumming School of Medicine, University of Calgary; 🇨🇦 Calgary, Alberta, Canada